Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Copanlisib (BAY80-6946)
Drug: Placebo
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Bendamustine
Drug: Prednisone

First Posted Date: 2015-12-10

Last Posted Date: 2024-12-11

Lead Sponsor: Bayer

Target Recruit Count: 551

Registration Number: NCT02626455

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States
🇧🇷
Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷
Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil

and more 198 locations

MabionCD20 Compared to MabThera in Lymphoma Patients

Phase 3

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: prednisone

First Posted Date: 2015-12-01

Last Posted Date: 2023-10-25

Lead Sponsor: Mabion SA

Target Recruit Count: 143

Registration Number: NCT02617485

Locations: 🇬🇪
Medulla - Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇭🇷
GH "dr.Josip Bencevic", Slavonski Brod, Croatia
🇭🇷
CHC Zagreb, Zagreb, Croatia

and more 32 locations

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Phase 3

Recruiting

Conditions: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Nilotinib
Drug: Methotrexate
Drug: Aracytine (Ara C)
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Drug: Depomedrol
Drug: Dexamethasone
Drug: Vincristine
Drug: Imatinib
Drug: 6 Mercaptopurine (6MP)

First Posted Date: 2015-11-20

Last Posted Date: 2019-10-21

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 265

Registration Number: NCT02611492

Locations: 🇫🇷
Hopital Saint Louis, Paris, France

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

Interventions: Drug: Atezolizumab
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Obinutuzumab
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2015-11-04

Last Posted Date: 2021-05-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT02596971

Locations: 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States

and more 18 locations

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Phase 1

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2015-11-03

Last Posted Date: 2017-05-23

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Registration Number: NCT02595242

Locations: 🇨🇳
Tianjin people's Hospital, Tianjin, China

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Entospletinib
Drug: Vincristine

First Posted Date: 2015-10-06

Last Posted Date: 2019-04-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 10

Registration Number: NCT02568683

Locations: 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, NORD Pas-de-calais, France
🇫🇷
Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France
🇫🇷
Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France

and more 4 locations

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: ITMHA
Drug: Dexamethasone
Drug: Mitoxantrone
Drug: Pegaspargase
Drug: Asparaginase Erwinia Chrysanthemi
Drug: Bortezomib
Drug: Vorinostat
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Leucovorin Calcium
Drug: Cytarabine
Drug: Etoposide
Drug: Vincristine

First Posted Date: 2015-09-17

Last Posted Date: 2024-01-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 50

Registration Number: NCT02553460

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States

and more 14 locations